Treatment-associated adverse events (≥ 10%)
| Adverse event . | Lenalidomide dose . | |||||
|---|---|---|---|---|---|---|
| Continuous daily dosing (n=100) . | 21-day dosing (n = 114) . | All patients (n = 214) . | ||||
| Any grade . | Grade 3 or 4 . | Any grade . | Grade 3 or 4 . | Any grade . | Grade 3 or 4 . | |
| Neutropenia | 30 | 27 | 26 | 23 | 28 | 25 |
| Thrombocytopenia | 31 | 22 | 22 | 18 | 26 | 20 |
| Rash | 24 | 2 | 20 | 6 | 22 | 4 |
| Pruritus | 21 | 1 | 21 | 1 | 21 | 1 |
| Constipation | 17 | 0 | 13 | 1 | 15 | 1 |
| Diarrhea | 16 | 1 | 13 | 1 | 15 | 1 |
| Fatigue | 18 | 4 | 13 | 4 | 15 | 4 |
| Peripheral edema | 3 | 0 | 16 | 1 | 10 | 1 |
| Nausea | 11 | 2 | 6 | 0 | 8 | 1 |
| Adverse event . | Lenalidomide dose . | |||||
|---|---|---|---|---|---|---|
| Continuous daily dosing (n=100) . | 21-day dosing (n = 114) . | All patients (n = 214) . | ||||
| Any grade . | Grade 3 or 4 . | Any grade . | Grade 3 or 4 . | Any grade . | Grade 3 or 4 . | |
| Neutropenia | 30 | 27 | 26 | 23 | 28 | 25 |
| Thrombocytopenia | 31 | 22 | 22 | 18 | 26 | 20 |
| Rash | 24 | 2 | 20 | 6 | 22 | 4 |
| Pruritus | 21 | 1 | 21 | 1 | 21 | 1 |
| Constipation | 17 | 0 | 13 | 1 | 15 | 1 |
| Diarrhea | 16 | 1 | 13 | 1 | 15 | 1 |
| Fatigue | 18 | 4 | 13 | 4 | 15 | 4 |
| Peripheral edema | 3 | 0 | 16 | 1 | 10 | 1 |
| Nausea | 11 | 2 | 6 | 0 | 8 | 1 |
Data are percentages.